Newly identified target may help with drug discovery for chronic inflammatory diseases

July 25, 2018, University of California - San Diego

Inflammation is part of the body's natural healing process. But when it becomes chronic, inflammation can lead to cancer, Alzheimer's disease and other conditions. Inflammasomes—protein-based molecular machines—trigger inflammation in response to different signals generated by cell stress, tissue injury or infectious organisms.

In a study published online July 25 in the journal Nature, University of California San Diego School of Medicine researchers identified a signaling pathway that activates the NLRP3 inflammasome implicated in several severe chronic inflammatory disorders.

"It has been obvious for some time that, when available, drugs that turn off the NLRP3 inflammasome, but not other inflammasomes, will be very useful for treating a variety of inflammatory disorders, from osteoarthritis to Alzheimer's disease and cancer," said Zhenyu Zhong, Ph.D., first author and UC San Diego School of Medicine postdoctoral researcher. "Until now, it was not clearly understood how environmental stress and activate the NLRP3 inflammasome and, without such knowledge, it was impossible to rationally design specific inhibitors of the NLRP3 inflammasome."

Interleukin 1β (IL-1β) is an inflammatory cytokine or hormone responsible for beneficial and adverse effects of . Normally, IL-1β is produced in very low amounts, but in response to injury, , infection or chronic inflammation, production of IL-1β is highly increased.

Production and secretion of IL-1β is regulated by inflammasomes. In addition to an enzyme called caspase-1, inflammasomes contain sensor proteins that respond to different signals generated by , tissue injury or . One of the most important and versatile sensors is NLRP3, which is responsible for activation and IL-1β production in response to tissue injury or different microparticles, including asbestos and silica dust. NLRP3 activators include microcrystals of cholesterol or uric acid, which trigger the inflammation associated with atherosclerosis or gout, respectively.

Working with Michael Karin, Ph.D., Distinguished Professor of Pharmacology and Pathology, Zhong and colleagues describe the critical role that the enzyme cytosine monophosphate kinase 2 (CMPK2) plays in the activation of NLRP3 and IL-1β production and subsequently in chronic inflammatory disorders. CMPK2 belongs to a family of enzymes called nucleotide kinases, some of whose members have already been successfully targeted by the pharmaceutical industry.

"I predict that specific inhibitors of CMPK2 can be easily and rapidly developed," said Karin, senior author. "Once available, such compounds may provide us with new treatments for many diverse untreatable and common illnesses, including osteoarthritis, Alzheimer's disease and lung cancer."

According to Karin, in gout and osteoarthritis CMPK2 inhibitors might reduce inflammation, pain and tissue damage. In Alzheimer's and Parkinson's, they may slow progression and loss of cognitive function.

A recent, unaffiliated trial showed that administering an antibody targeting IL-1β reduces the likelihood of a second cardiac infarction in patients who already have undergone one heart attack. Further analysis of the data found that it had an even greater positive effect in patients with lung cancer, Karin said.

"Unlike IL-1β antibody, which blocks IL-1β that is produced in response to bacterial infections, the CMPK2 inhibitor will only prevent IL-1β induction in response to tissue injury or micro particles," said Karin.

Explore further: Molecular 'brake' prevents excessive inflammation

More information: Zhenyu Zhong et al, New mitochondrial DNA synthesis enables NLRP3 inflammasome activation, Nature (2018). DOI: 10.1038/s41586-018-0372-z

Related Stories

Molecular 'brake' prevents excessive inflammation

February 25, 2016
Inflammation is a Catch-22: the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and sometimes leading to organ failure and death. ...

Immune system 'double agent' could be new ally in cancer fight

March 16, 2018
St. Jude Children's Research Hospital scientists have discovered that an enzyme called TAK1 functions like a "double agent" in the innate immune response, serving as an unexpected regulator of inflammation and cell death. ...

Inflammatory signals in heart muscle cells linked to atrial fibrillation

June 4, 2018
Interfering with inflammatory signals produced by heart muscle cells might someday provide novel therapeutic strategies for atrial fibrillation, according to an international team of researchers who have published their findings ...

Researchers uncover key role for microRNA in inflammatory bowel disease

May 9, 2017
An international team of researchers has discovered that a microRNA produced by certain white blood cells can prevent excessive inflammation in the intestine. The study, "Myeloid-derived miR-223 regulates intestinal inflammation ...

Scientists make surprising finding in stroke research

March 16, 2015
Scientists at The University of Manchester have made an important new discovery about the brain's immune system that could lead to potential new treatments for stroke and other related conditions.

Could a ketogenic diet alleviate gout?

February 28, 2017
More than 8 million individuals in the United States have gout, a disease that can cause intense recurrent episodes of debilitating pain, inflammation, and fever. The cause of gout is the accumulation of urate crystals in ...

Recommended for you

Inflammation can lead to circadian sleep disorders

October 31, 2018
Inflammation, which is the root cause of autoimmune disorders including arthritis, Type 1 diabetes, irritable bowel syndrome and Crohn's disease, has unexpected effects on body clock function and can lead to sleep and shiftwork-type ...

Machine learning tool predicts the potential of peptides as immune activators

October 23, 2018
The immune system keeps T cells under control by regulating precisely when they can respond to a pathogen. For instance, helper T cells only turn "on" if other immune cells, such as antigen-presenting cells (APCs) present ...

A new mechanism in the control of inflammation

October 18, 2018
After infection or tissue injury, the inflammatory immune response attacks the infection and repairs the damaged tissue. However, sometimes excess inflammation can have the opposite effect, increasing injury in a process ...

Sugar, a 'sweet' tool to understand brain injuries

October 15, 2018
Australian researchers have developed ground-breaking new technology which could prove crucial in treating brain injuries and have multiple other applications, including testing the success of cancer therapies.

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

Microbiome profiling reveals associations with ulcerative colitis severity, treatment

October 11, 2018
A study of gut microbes from more than 400 children points to how the microbiome behaves in this inflammatory bowel disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.